Rubaba Hussain, MD
Family Medicine · Clark, NJNPI 1194913681
Payments from drug & device makers
Across 794 payments — averaging $4737.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1M
- Pfizer$861K
- Alnylam Pharmaceuticals Inc.$409K
- Cue Health Inc.$396K
- Sanofi Pasteur Inc.$287K
- GSK$251K
- plus $549K from 12 others
Across 8 payments — averaging $10,199 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$81K
- GSK$763
What the payments were for
- Travel & lodging$45837%
- Food & beverage$77663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 23 | $1,007,990 |
| Pfizer | 60 | $861,048 |
| Alnylam Pharmaceuticals Inc. | 605 | $409,165 |
| Cue Health Inc. | 1 | $395,849 |
| Sanofi Pasteur Inc. | 25 | $287,099 |
| GSK | 41 | $251,341 |
| Sanofi US Services Inc. | 11 | $141,211 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $116,146 |
| Merck | 5 | $88,304 |
| Romark Laboratories, LC | 3 | $71,927 |
| Novartis | 3 | $49,417 |
| IBSA Institut Biochimique SA | 3 | $38,660 |
| Modernatx, Inc. | 2 | $20,900 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $9,100 |
| Orasure Technologies Inc. | 1 | $7,650 |
| Vanda Pharmaceuticals Inc. | 1 | $5,500 |
| Merz North America, Inc. | 3 | $220 |
| Novo Nordisk | 1 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,761,647 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $541 |
| Fluticasone Propionate | 25 | $157 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $135 |
| Azithromycin | 23 | $97 |
| Ibuprofen | 31 | $55 |
| Amoxicillin | 12 | $27 |
| Prednisone | 19 | $9 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Clark
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.